Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G/A SPRUCE BIOSCIENCES, INC. Filed by: Alyeska Investment Group, L.P.

May 15, 2026 4:52 PM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Alyeska Investment Group, L.P.
Signature:Jason Bragg
Name/Title:Jason Bragg | Chief Financial Officer
Date:05/15/2026
Alyeska Fund GP, LLC
Signature:Jason Bragg
Name/Title:Jason Bragg | Chief Financial Officer
Date:05/15/2026
Anand Parekh
Signature:Anand Parekh
Name/Title:Anand Parekh | Self
Date:05/15/2026
Exhibit Information

As of March 31, 2026, the Reporting Persons beneficially own 61,670 shares of Common Stock, consisting of (i) 21,671 shares of Common Stock, (ii) 9,999 shares issuable upon exercise of warrants, and (iii) 30,000 shares acquired in a private placement. The number of shares of Common Stock outstanding (1,372,043) is based on the Form 424B5 dated March 9, 2026. Position held by Alyeska Master Fund, L.P. Alyeska Investment Group, L.P., as investment manager, exercises voting and investment control over the shares held by Alyeska Master Fund, L.P. Anand Parekh, as Chief Executive Officer of Alyeska Investment Group, L.P., may be deemed the beneficial owner of such shares. Mr. Parekh disclaims beneficial ownership of such shares. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Categories

SEC Filings